Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease
Brian G. Feagan(Western University), William J. Sandborn(Western University), Christopher Gasink(Western University), Douglas Jacobstein(Western University), Yinghua Lang(Western University), Joshua R. Friedman(Western University), Marion Blank(Western University), Jewel Johanns(Western University), Long-Long Gao(Western University), Miao Ye(Western University), Omoniyi J. Adedokun(Western University), Bruce E. Sands(Western University), Stephen B. Hanauer(Northwestern University), Séverine Vermeire(Western University), Stephan R. Targan(Western University), Subrata Ghosh(Western University), Willem J. de Villiers(Western University), Jean–Frédéric Colombel(Western University), Zsolt Tulassay(Semmelweis University), Ursula Seidler(Western University), Bruce Salzberg(Western University), Pierre Desreumaux(Western University), Scott D. Lee(Western University), Edward V. Loftus(Western University), Levinus A. Dieleman(Western University), Seymour Katz(Western University), Paul Rutgeerts(Western University)
Cited by 1,789Open Access
Abstract
Ustekinumab, a monoclonal antibody to the p40 subunit of interleukin-12 and interleukin-23, was evaluated as an intravenous induction therapy in two populations with moderately to severely active Crohn's disease. Ustekinumab was also evaluated as subcutaneous maintenance therapy.
Related Papers
No related papers found
Powered by citation graph analysis